Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 286

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer

Open access
Hoeppner, Jens, Brunner, Thomas, Schmoor, Claudia, Bronsert, Peter, Kulemann, Birte, Claus, Rainer, Utzolino, Stefan, Izbicki, Jakob Robert, Gockel, Ines, Gerdes, Berthold, Ghadimi, Michael, Reichert, Benedikt, Lock, Johan F., Bruns, Christiane, Reitsamer, Ernst, Schmeding, Maximillian, Benedix, Frank, Keck, Tobias, Folprecht, Gunnar, Thuss-Patience, Peter, Neumann, Ulf Peter, Pascher, Andreas, Imhoff, Detlef, Daum, Severin, Strieder, Tanja, Krautz, Christian, Zimmermann, Simone, Werner, Jens, Mahlberg, Rolf, Illerhaus, Gerald, Grimminger, Peter, Lordick, Florian·2025·New England Journal of Medicine

Abstract

BACKGROUND: The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy. METHODS: In this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients with resectable esophageal adenocarcinoma to receive perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery. Eligibility criteria included a primary tumor with a clinical stage of cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease, in which T indicates the size and extent of the tumor (higher numbers indicate a more advanced tumor), and N indicates the presence (N+) or absence (N0) of cancer spread to the lymph nodes, without evidence of metastatic spread. The primary end point was overall survival. RESULTS: From February 2016 through April 2020, we assigned 221 patients to the FLOT group and 217 patients to the preoperative-chemoradiotherapy group. With a median follow-up of 55 months, overall survival at 3 years was 57.4% (95% confidence interval [CI], 50.1 to 64.0) in the FLOT group and 50.7% (95% CI, 43.5 to 57.5) in the preoperative-chemoradiotherapy group (hazard ratio for death, 0.70; 95% CI, 0.53 to 0.92; P = 0.01). Progression-free survival at 3 years was 51.6% (95% CI, 44.3 to 58.4) in the FLOT group and 35.0% (95% CI, 28.4 to 41.7) in the preoperative-chemoradiotherapy group (hazard ratio for disease progression or death, 0.66; 95% CI, 0.51 to 0.85). Among the patients who started the assigned treatment, grade 3 or higher adverse events were observed in 120 of 207 patients (58.0%) in the FLOT group and in 98 of 196 patients (50.0%) in the preoperative-chemoradiotherapy group. Serious adverse events were observed in 98 of 207 patients (47.3%) in the FLOT group and in 82 of 196 patients (41.8%) in the preoperative-chemoradiotherapy group. Mortality at 90 days after surgery was 3.1% in the FLOT group and 5.6% in the preoperative-chemoradiotherapy group. CONCLUSIONS: Perioperative chemotherapy with FLOT led to improved survival among patients with resectable esophageal adenocarcinoma as compared with preoperative chemoradiotherapy. (Funded by the German Research Foundation; ESOPEC ClinicalTrials.gov number, NCT02509286.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2409408

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 286

Metadata

Authors
Hoeppner, J., Brunner, T., Schmoor, C., Bronsert, P., Kulemann, B., Claus, R., Utzolino, S., Izbicki, J. R., Gockel, I., Gerdes, B., Ghadimi, M., Reichert, B., Lock, J. F., Bruns, C., Reitsamer, E., Schmeding, M., Benedix, F., Keck, T., Folprecht, G., Thuss-Patience, P., Neumann, U. P., Pascher, A., Imhoff, D., Daum, S., Strieder, T., Krautz, C., Zimmermann, S., Werner, J., Mahlberg, R., Illerhaus, G., Grimminger, P., & Lordick, F.
Venue
New England Journal of Medicine
Published
2025-01-23
Volume
392
Issue
4
Pages
323-335
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4406717200
Cited by
286
References
14
FWCI
249.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2409408
The paper
Hoeppner, J., Brunner, T., Schmoor, C., Bronsert, P., Kulemann, B., Claus, R., Utzolino, S., Izbicki, J. R., Gockel, I., Gerdes, B., Ghadimi, M., Reichert, B., Lock, J. F., Bruns, C., Reitsamer, E., Schmeding, M., Benedix, F., Keck, T., Folprecht, G., . . . Lordick, F. (2025). Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2409408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.